Adjuvant Treatment for Stage III Melanoma in the Era of Targeted Medicine and Immunotherapy

Overview

Journal Melanoma Manag

Date 2018 Sep 8

PMID 30190882

Authors

Eytan Ben-Ami

Jacob Schachter

Affiliations

Soon will be listed here.

Abstract

The accelerated development in the treatment of metastatic melanoma, both in molecular targeted therapy and immunotherapy, is already starting to impact on adjuvant therapy in stage III melanoma. Following the approval of ipilimumab for adjuvant therapy in melanoma, clinical trials assessing other checkpoint modulators and MAPK pathway inhibitors as adjuvant treatments for melanoma are currently ongoing. As results from these trials mature in the next few years, a change in the landscape of adjuvant treatment for melanoma is expected, resulting in new challenges in treatment decisions such as optimizing patients selection through predictive and prognostic biomarkers, and management of treatment related adverse events, in particular immune related toxicities.

References

Moschos S, Edington H, Land S, Rao U, Jukic D, Shipe-Spotloe J . Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006; 24(19):3164-71. DOI: 10.1200/JCO.2005.05.2498. View

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View

Seremet T, Lienard D, Suppa M, Trepant A, Rorive S, Woff E . Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. Melanoma Res. 2015; 25(2):180-3. DOI: 10.1097/CMR.0000000000000145. View

Ivashkiv L, Donlin L . Regulation of type I interferon responses. Nat Rev Immunol. 2013; 14(1):36-49. PMC: 4084561. DOI: 10.1038/nri3581. View

Lipton A, Harvey H, Lawrence B, Gottlieb R, Kukrika M, Dixon R . Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer. 1983; 51(1):57-60. DOI: 10.1002/1097-0142(19830101)51:1<57::aid-cncr2820510114>3.0.co;2-v. View

Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D . Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009; 27(6):939-44. DOI: 10.1200/JCO.2008.16.3121. View

Corrie P, Marshall A, Dunn J, Middleton M, Nathan P, Gore M . Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 2014; 15(6):620-30. DOI: 10.1016/S1470-2045(14)70110-X. View

Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K . A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer. 2002; 94(2):470-6. DOI: 10.1002/cncr.10186. View

Tarhini A, Edington H, Butterfield L, Lin Y, Shuai Y, Tawbi H . Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705. PMC: 3912016. DOI: 10.1371/journal.pone.0087705. View

10.

Shah G, Socci N, Gold J, Wolchok J, Carvajal R, Panageas K . Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Ann Oncol. 2010; 21(8):1718-1722. DOI: 10.1093/annonc/mdp593. View

11.

Isaacs A, Lindenmann J . Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957; 147(927):258-67. DOI: 10.1098/rspb.1957.0048. View

12.

Grosso J, Jure-Kunkel M . CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013; 13:5. PMC: 3559193. View

13.

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

14.

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

15.

Petrella T, Verma S, Spithoff K, Quirt I, McCready D . Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol (R Coll Radiol). 2012; 24(6):413-23. DOI: 10.1016/j.clon.2011.12.002. View

16.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

17.

Eggermont A, Suciu S, MacKie R, Ruka W, Testori A, Kruit W . Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005; 366(9492):1189-96. DOI: 10.1016/S0140-6736(05)67482-X. View

18.

Sabel M, Sondak V . Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist. 2003; 8(5):451-8. DOI: 10.1634/theoncologist.8-5-451. View

19.

Laks S, Brueske K, Hsueh E . Neoadjuvant treatment of melanoma: case reports and review. Exp Hematol Oncol. 2014; 2(1):30. PMC: 3832230. DOI: 10.1186/2162-3619-2-30. View

20.

Francisco L, Sage P, Sharpe A . The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236:219-42. PMC: 2919275. DOI: 10.1111/j.1600-065X.2010.00923.x. View